Juvenile neuronal ceroid-lipofuscinosis: Clinical and molecular investigation in a large family in Brazil;Lipofuscinose ceróide neuronal juvenil: Investigação clínica e molecular em uma família grande no Brasil

Arquivos de Neuro-Psiquiatria

Volumn 69, Issue 1, 2011, Pages 13-18

  Valadares, Eugênia Ribeiro ^a   Pizarro, Mayara Xavier ^a   Oliveira, Luiz Roberto ^a   de Amorim, Regina Helena Caldas ^a   Magalhães Pinheiro, Tarcísio Márcio ^a   Grieben, Ulrike ^b   Santos, Helena Hollanda ^a   Queiroz, Rachel Rabelo ^a   de Castro Lopes, Guilherme ^a   Brunialti Godard, Ana Lúcia ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Otto Heubner Zentrum für Kinder und Jugendmedizin   (Germany)

Author keywords

Batten disease; Neuronal ceroid lipofuscinoses; Polymerase chain reaction

Indexed keywords

ARTICLE; AUTISM; BRAZIL; CHILD; CLINICAL ARTICLE; CONSANGUINITY; DISEASE SEVERITY; FAMILIAL DISEASE; FEMALE; GENETIC COUNSELING; HUMAN; MALE; NEURONAL CEROID LIPOFUSCINOSIS; NIGHT BLINDNESS; PARKINSONISM; PHENOTYPE; TIC; VISUAL DISORDER;

EID: 79952337389     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/s0004-282x2011000100004     Document Type: Article

References (15)

1. IEM Digest. The function of CLN3P, the Batten disease protein. Mol Gen Metab 2008;93:269-274.
2. Peltonen L, Savukoski M, Vesa J. Genetics of the neuronal ceroid lipofuscinoses. Current Opinion in Gen Dev 2000;10:299-305.
3. Kovács AD, Pearce DA. Attenuation of AMPA receptor activity improves motor skills in a mouse model of juvenile Batten disease. Exp Neurol 2008; 209:288-291.
4. Teixeira C, Guimarães A, Bessa C, et al. Clinicopathological and molecular characterization of neuronal ceroid-lipofuscinoses in the Portuguese population. J Neurol 2003;250:661-667.
5. Wisniewski KE, Kida E, Connell F, Zhong N. Neuronal ceroid lipofuscinoses: research update. Neurol Sci 2000;21(Suppl):S49-S56.
6. Persaud-Sawin DA, Mousallem T, Wang C, Zucker A, Kominami E, Boustany RM. Neuronal ceroid-lipofuscinoses: a common pathway? Pediatr Res 2007; 61:146-152.
7. Mitchison HM, Munroe PB, O'Rawe AM, et al. Genomic structure and complete nucleotide sequence of the batten disease gene, CLN3. Genomics 1997;40:346-350.
8. Järvelä I, Mitchison HM, Munroe PB, O'Rawe AM, Mole SE, Syvanen AC. Rapid diagnostic test for the major mutation underlying Batten disease. J Med Genet 1996;33:1041-1042.
9. Kwon JM, Rothberg PG, Leman AR, Weimer JM, Mink JW, Pearce DA. Novel CLN3 mutation predicted to cause complete loss of protein function does not modify the classical JNCL phenotype. Neuroscience Letters 2005; 387:111-114.
10. Wisniewski KE, Kaczmarski A, Kida E, et al. Reevaluation of neuronal ceroid lipofuscinoses: atypical juvenile onset may be the result of CLN2 mutations. Mol Gen Metab 1999;66:248-252.
11. Järvelä I, Autti T, Lamminranta S, Aberg L, Raininko R, Santavuori P. Clinical and magnetic resonance imaging findings in Batten disease: analysis of the major mutation (1.02-kb deletion). An Neurol 1997;42:799-802.
12. Bäckman ML, Santavuori PR, Åberg LE, Aronen ET. Psychiatric symptoms of children and adolescents with juvenile neuronal ceroid-lipofuscinoses. J Intellec Disab Res 2005;49:25-32.
13. Munroe B, Mitchison HM, O'Rawe AM, et al. Spectrum of mutations in the Batten disease gene, CLN3. Am J Hum Genet 1997;61:310-316.
14. Taschner PEM, Vos N, Breuning MH. Rapid detection of the major deletion in the Batten disease gene CLN3 by allele specific PCR. J Med Genet 1997; 34:955-956.
15. Miller TM, Johnston C. Should the Babinski sign be part of the routine neurologic examination? Neurology 2005;65:1165-1168.